ForPatients
by Roche

HER2-positive Early Breast Cancer

A study to evaluate the use of a fixed-dose combination of pertuzumab and trastuzumab given as an injection under the skin for treating people with HER2-positive early breast cancer

Trial Status	Trial Runs In	Trial Identifier
Completed	1 Countries	2023-509321-50-00 ML42502

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

2023-509321-50-00 ML42502
Trial Identifiers

Eligibility Criteria:

Gender	Age	Healthy Volunteers
	All	

© 2022 F. Hoffmann-La Roche Ltd